evaluation of lisedexamfetamine dimesylate in tratment of binge eating disorder alone and in combination with topiramte in edults

Comprehensive evaluation of lisedexamfetamine dimesylate in tratment of binge eating disorder alone and in combination with topiramte in 18_55 year_old edults

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230910059396N1

Enrollment

Registered

2023-11-04

Start date

2023-09-16

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Binge eating disorder. Binge eating disorder

Interventions

Intervention 1: Intervention group: Patients received LDX (n=48) LDX (produced by tekaje pharmaceutical company) was titrated from 30 mg/day to a maximum of 50mg/day for 12weeks. Assessement is done

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Participants aged 18-55 years old meeting the diagnostic criteria for BED according to DSM-5

Exclusion criteria

Exclusion criteria: Posing other major psychiatric disorders assessed by psychiatris (anxiety ,depression,..) Posing physical disease like cardiovascular diseases, thyroid disturbances or gastrointestinal diseases known sensitivity to LDX or TPM.

Design outcomes

Primary

Measure	Time frame
Binge eating score. Timepoint: At first and 3months after. Method of measurement: Bing eating scale of gormally.	—

Secondary

Measure	Time frame
Body mass index. Timepoint: First qnd 3months after treatment. Method of measurement: Meter and wieght.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa taghavi

Islamic Azad University

Dr_mahsataghavi@yahoo.com+98 71 3634 1771

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026